Go to the ID21 home page

Insights
id21 logo ID21 Home
id21 logo Insights
id21 logo Insights Health #2
Delivering the goods: HIV treatment for the poor
Testing times: opportunities and challenges for voluntary counselling and testing
Quantity with quality: scaling-up VCT in rural Kenya
Providing care in South Africa: lessons from TB/HIV pilot districts
DOTS on the spot: lessons for access to HIV care
-
Economies of scale-up? The cost of expanding access
Local solutions: the role of district hospitals
Model of success: universal access to treatment in Brazil
Community action: mobilising NGOs and CBOs
Demanding control: HIV treatment in Haiti
Sites for sore eyes
- - -

February 2002 Insights Health Issue #2

Back to Insights Health #2

Local solutions
The role of district hospitals

Antiretroviral drugs (ARVs) are available for people with HIV/AIDS at certain specialist centres in developing countries. In Thailand, generic drug production is growing rapidly and prices have fallen by 80 percent over two years. But most patients are poor and cannot get to specialist centres. For wider access, district hospitals must play a role.

Médecins Sans Frontières are conducting operational research in Thailand with long-standing partners: the Thai Network of People living with HIV/AIDS and the Bang Kruai and Ban Laem District Hospitals. 88 adults and children have started three-drug ART treatment at these hospitals. Most have advanced disease. In the first six months of treatment, nearly all saw an improvement in their CD4 cell count.

Discussions revealed that district hospital staff are keen to provide ARV in order to:

  • improve services for patients
  • increase their own knowledge and potential
  • prevent new HIV infections
  • enhance their hospital's reputation
  • re-frame AIDS as a 'normal' disease.

But will increased availability of treatment encourage unsafe sex? Some centres in developing countries refuse to treat patients thought to have high-risk behaviour. Health workers here feel that they could advise patients on reducing risky behaviour. If 'high-risk' patients are excluded from treatment, this opportunity will be lost. Another concern of health workers is the potential for conflict if drug supplies are limited.

Seven patients in the study developed serious drug side-effects, requiring a change in treatment. However, milder side-effects, such as nausea, diarrhoea, headache and muscle pains, often improve within two to four weeks of starting treatment. Adherence can be improved by educating patients about side-effects and developing a plan to help them cope. Where possible, this should include peer support from other people with HIV/AIDS.

The researchers conclude that:

  • District hospitals can manage ARV treatment and most patients will benefit.
  • Enrolment should be based on medical rather than social or behavioural criteria.
  • Alternative ARVs must be supplied for patients who develop serious side-effects. Hospitals need clear guidelines on dealing with these problems.
  • Education and peer support, particularly relating to side-effects, can help patients adhere to treatment.

David Wilson
Médecins Sans Frontières in Thailand
311 Ladphrao 101
Wangtonglarng
Bangkok 10240
Thailand

T: +66 2375 6491
F: +66 2374 9835

msfbthai@ksc.th.com

Back to Insights Health #2

FREE Information Delivery services from ID21:
Get updates by email: ID21 news
ID21 is enabled by the UK Government Department for International Development(www.dfid.gov.uk) and hosted by the Institute of Development Studies (www.ids.ac.uk/ids), at the University of Sussex, UK. Charitable Company No. 877338. ID21 is a oneworld.net (www.oneworld.org) partner and a mediachannel affiliate (www.mediachannel.org).

Top of the page

Views expressed in INSIGHTS are not necessarily those of DFID, IDS, id21 or other contributing institutions. Copyright remains with the original authors but (unless stated otherwise) articles may be copied or quoted without restriction, provided id21 and originating author(s) and institution(s) are acknowledged.

Copyright © 2001 id21. All rights reserved.